Kirkland, WA – According to filings with the U.S. Securities and Exchange Commission, Prevencio is raising $9,524,635.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Rhonda Rhyne played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Prevencio
Prevencio, Inc., is Revolutionizing Blood Tests For Cardiovascular Disease Powered by Artificial Intelligence (AI). Prevencios value proposition is Preventing the Preventable That is, improving patient outcomes and clinical trials through more accurate blood tests for Cardiovascular Disease conditions. Prevencio utilizes Machine Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers + Proprietary Algorithms to deliver cardiovascular diagnostic & prognostic tests that are significantly more accurate than standard-of-care stress tests, individual biomarkers, genetic markers and clinical risk scores.

To learn more about Prevencio, visit http://www.prevenciomed.com/

Contact:
Rhonda Rhyne, Chief Executive Officer
858-204-4116
rrhyne@prevenciomed.com
https://www.linkedin.com/in/rhondarhyne/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved